GERMANY - Heidelberg Innovation and BioMed Venture exit BioVision

Venture capital groups Heidelberg Innovation and BioMed Venture have exited their stakes in BioVision GmbH to US-based molecular spectroscopy systems specialist Digilab LLC. Heidelberg Innovation and BioMed Venture, alongside other investors provided EUR 15m of expansion financing to the Hannover-based peptide profiling specialist in 2002. Since then the company has developed relationships with leading life science companies to facilitate their peptide biomarker diagnostic and therapeutic discovery needs. This is Heidelberg Innovation's second exit this year, following the sale of Microcuff GmbH to Kimberly Clarke Corporation in February.